-- National Cancer Institute in Bethesda, Maryland
-- Albany Medical Center in Albany, New York
-- John Wayne Cancer Center in Santa Monica, California
-- Moffitt Cancer Center in Tampa, Florida
-- Morristown Memorial Hospital in Morristown, New Jersey
-- Providence Cancer Center in Portland, Oregon
-- St. Luke's Cancer Center of Bethlehem, Pennsylvania
-- Swedish Medical Center in Englewood, Colorado
-- University of Maryland Medical Center in Baltimore, Maryland
-- University of Texas Medical Branch in Galveston, Texas
Delcath is announcing the expansion of this trial following Providence
entering into a clinical research agreement with Delcath. Walter J. Urba,
M.D., Ph.D., Medical Director of the Robert W. Franz Cancer Research Center
and Earle A. Chiles Research Institute -- a part of the Providence Cancer
Center -- will serve as the Principal Investigator of the study.
Commenting on joining this Phase III study, Dr. Urba stated, "Providence is
excited and motivated to be joining this promising trial. Melanoma
metastasized to the liver leaves patients with few options, and Providence
Cancer Center is eager to offer this treatment modality to our patients.
Regional therapy has shown impressive results for unresectable cancer of
the liver, and targeting the liver with high doses of drug focuses this
technique towards the most pressing and life-limiting organ. We look
forward to joining the other leading cancer centers involved with this
trial to bring these patients a much needed treatment option."
"The addition of Providence Cancer Center to this trial further propels
Delcath towards its goal of completing enrollment in 2009," commented
Richard L. Taney, President and CEO of Delcath. "For decades, Dr. Urba has
been a leader in the research and implementation of melanoma treatments and
he brings to this trial significant clinical and academic experience.
Patients suffering from this devastating disease now have a number of
leading cancer centers throughout the United States to turn to for this
treatment modality and we look forward to continuing this progress."
About Providence Cancer Center
Providence Cancer Center serves more cancer patients than any other health
system in Oregon. Here, patients and families benefit from some of the
finest, most comprehensive cancer services in the world, including the best
in diagnostic imaging, state-of-the-art treatments, nationally renowned
research, and compassionate counseling and support. Our doctors, nurses,
researchers, patient advocates and other caregivers work together to treat
cancer aggressively and to ensure that no person has to face the challenge
of a cancer diagnosis alone.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents
on a worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.
Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper Cass Almendral (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006